Creative Medical Technologies Licenses Patient-Specific Adult Stem Cell Therapy for Male Infertility
Clinical Stage Adult Stem Cell Company Expands Portfolio of Clinical Indications
Creative Medical Technologies, Inc. (CMT) announced today the signing of a license agreement with LA BioMed granting exclusive rights for United States patent application # 14/508763, covering the use of stem cells for treatment of male infertility. In the patent application and a subsequent publication, Ronald S.
New Study Finds a 16% Reduction in Cardiovascular Events with the Use of ACEIs and ARBs
Two classes of blood pressure medications, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are associated with a 16% lower risk of strokes, heart attacks and death in patients with end-stage renal disease who are undergoing peritoneal dialysis, a new study in the journal, Nephrology Dialysis Transplantation, reports.
They Find Study “Reassuring” and Say it Has Lessons for Cardiologists and Oncologists
In an editorial in the New England Journal of Medicine, LA BioMed Researchers Rowan T. Chlebowski, MD, PhD, and Matthew J. Budoff, MD, said a new study of the long-term use of aromatase inhibitors to prevent the recurrence of certain types of breast cancer is “reassuring,” and they urged oncologists and cardiologists to combine prevention and early detection to prevent disease.